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Basic features 
 PE is relatively common cardiovascular emergency  
 By occluding the pulmonary arterial bed it may lead to acute life-
threatening (3% early mortality) but potentially reversible right 
ventricular failure 
 PE is a difficult diagnosis that may be missed because of non-specific 
clinical presentation. 
 Early diagnosis is fundamental, since immediate treatment is highly 
effective  
 Despite the availability of diagnostic tools, mis-diagnosis of PE 
happens with frequency greater than 10% 
Medical history 
 Male, aged 42 years, working in service provision, reduced physical activity with 
increased body weight about 20kg, for the last two years, previously active athlete 
(one year received protein supplements and creatine, then TT 80 kg) 
 
 Symptoms: two weeks prior to hospitalization general flu-like symptoms that 
lasted several days followed by light febrile state and episode of fatigue on exertion 
a week prior to hospitalization, that was repeated the next day and day after at a 
lower level of effort, and two days before hospital admission present at rest, 
followed by a feeling of breathlessness 
 
 Signs: BP 135/85mmHg, HR 100-110/min, eupnoea, O2 saturation > 94%, 
afebrile, remain physical findings without any apparent departure 
  BMI 30 – obesity 
ECG at admission 
S1Q3T3, sinus tachycardia, nonspecific ST-T wave changes 
Clinical probability of PE Wells score  and revised Geneva score 
Revised Geneva score Wells score 
Variable Points Variable Points 
Predisposing factors Predisposing factors 
Age >65 years +1 
Previous DVT or PE +3 Previous DVT or PE + 1.5 
Surgery or fracture within 1 month +2 Recent surgery or immobilization + 1.5 
Active malignancy +2 Cancer + 1 
Symptoms Symptoms 
Unilateral lower limb pain + 3 
Haemoptysis + 2 Haemoptysis + 1 
Clinical signs Clinical signs 
Heart rate Heart rate 
75-94 beats/min + 3 >100 beats/min + 1.5 
≥ 95 beats/min + 5 
Pain on lower limb deep vein at 
palpation and unilateral edema 
+ 4 Clinical signs of DVT + 3 
Clinical judgment 
Alternative diagnosis less likely than PE 
+ 3 
Clinical probability Total Clinical probability (3 levels) Total 
Low 0-3 Low 0-1 
Intermediate 4-10 Intermediate 2-6 
High ≥11 High ≥7 
Clinical probability (2 levels) 
PE unlikely 0-4 
PE likely >4 
Diagnostic strategies for suspected non-high-risk PE 
PTE - Diagnosis 
 D-dimmer  level ​​in our patient – 2200 ng/ml (<500) 
 
• CUS (compression venous ultrasonography) of lower limbs 
- a negative finding 
 
Typical echocardiographic image of PE involves the presence 
of three groups of criteria: 
1.Criteria for right ventricular overload (present  ≥1) presence of thrombus  
in RV cavities,  RV diastolic dimension > 30mm in parasternal section or 
RV / LV terms  > 1, systolic flattening of IPC, acceleration time <90 msec,  
or pressure gradient TV > 30mmHg  in the absence of RV hypertrophy 
2. 60-60 mark: acceleration time during RV ejection 60 msec in the 
presence of pressure gradient of tricuspid regurgitation by 60mmHg 
3. McConnell sign: Normo / hyperkinesia of the apical segment, with 
hypo / akinesia of the free wall of RV 
In our patient: 
 RV diastolic dimension > 30mm in parasternal section  
 RV / LV terms  > 1 
 acceleration time <90 msec 
 pressure gradient TV > 30mmHg  in the absence of RV 
hypertrophy 
 McConnell sign + 
- Presence of massive thrombs in both pulmonary arteries, right with complete obstruction 
of the lumen. 
- Truncus pulmonalis with diameter up to 33 mm 
 
CT findings in addition to MASSIVE BILATERAL PULMONARY THROMBOEMBOLISM 
markers for risk stratification   
-three key components- 
PE-related early 
MORTALITY RISK 
RISK MARKERS Potential 
treatment 
implications 
KLINICAL  
(schok or 
hypotension) 
RV 
dysfunction 
Myocardial 
injury 
HIGH (>15%) + (+)a (+)a Trombolysis or 
or embolectomy 
embolectomy 
 
NON-HIGH 
Inter 
mediate 
(3-15%) 
- + + Hospital 
admission + - (troponin ) 
- + 
Low 
(˂ 1 %) 
- - - Early discharge 
discharge or 
home treatment 
treatment 
Recommendations: treatment for Non-high-risk PTE 
Anticoagulation should be initiated without delay in patients with high or 
intermediate clinical probability of PE while diagnostic workup is still 
ongoing 
I C 
Use of LMWH or fondaparinux is the recommended form of initial 
treatment  for most patients with non-high-risk PE 
I A 
In patients at high risk of bleeding and in those with severe renal 
dysfunction, unfractionated heparin with an aPTT target range 
of 1.5–2.5 times normal is a recommended form of initial treatment 
I C 
In patients at high risk of bleeding and in those with severe renal 
dysfunction, unfractionated heparin with an aPTT target range of 1.5–2.5 
times normal is a recommended form of initial treatment 
Initial treatment with unfractionated heparin, LMWH or fondaparinux 
should be continued for at least 5 days and I A may be replaced by 
vitamin K antagonists only after achieving target INR levels for at least 2 
consecutive days 
I 
I 
A 
C 
Routine use of thrombolysis in non–high-risk PE patients is not 
recommended, but it may be considered in selected patients 
with intermediate-risk PE 
IIb B 
Thrombolytic therapy should be not used in patients with low-risk PTE III B 
Anticoagulant treatment and response threw parameters of hemostasis 
in our patient 
date date date date date date 
PARAMETER Normal values 5.02 8.02 11.02 14.02 15.02 18.02 
Tr 150-450 186 255 214 264 254 224 
Htc 35-45% 44 45 41 46 42 43 
PT 13 sec 13* 11* 12* 17 18 14 
aPTT 32sec 28* 23* 28* 32 33 28 
TT 20 sec 20* 16* 19* 15 20 20 
INR 1 from 
7.02** 
 
1.13** 
 
1.5 
 
1.2 
Anti Xa <0.30 IU/ml *** *** 1.2*** 1.29*** 
D dimer <500ng/ml 2200 3700 4500 >4500 <3000 
Legend:    *UFH 30000/24h continuous i.v. infusion 
  ** UFH + OAK  
  ***LMWH (0.9ml/12h)+ OAK 
HEPARIN RESISTANCE 
 Situations where patients require unusually high doses of heparin to 
achieve therapeutic aPTT level 
In the clinical setting - PTE patients who require >35000 IU/24 hours 
to achieve therapeutic aPTT levels are defined in this category 
 
Possible mechanisms: 
 AT deficiency 
  clearance of heparin 
  levels of heparin binding proteins (PF4, fib, fVIII and histidine rich glycoprotein) 
 high values ​​of the factor VIII or fibrinogen 
 inability of inactivation of factor Xa bound to platelets 
 inability to deactivate thrombin bound to fibrin 
 reduction of AT quantities under the influence of heparin 
 some medications (NTG, aprotinin)   
 
Parenteral Anticoagulants. Antithrombotic Therapy and Prevention of  Thrombosis, 9th ed: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines  
Heparin resistance- causes and possible solutions 
   REASONS FOR LACK OF RESPONSE TO UFH : 
 Low dose of the UFH (fixed dose regimen) 
 Validity of the test (aPTT) 
 technical limitations of aPTT 
 variable response of aPTT to heparin 
 SOLUTIONS 
 In patients who require high doses of heparin to achieve therapeutic aPTT 
value, measuring anti Xa activity is more appropriate test 
 Replacing of UFH with LMWH is one of the sollutions 
Parenteral Anticoagulants. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines  
ECG during hospital stay – after therapy 
signs of RV overload- inversion of T waves in leads V1-V4,  
   QR form in V1 lead 
RV function in time of diagnosis and after 14 days 
CLINICAL COURSE OF OUR PATIENT 
 
 -clinically stable 
 -haemodynamically stable 
 -improvement of right ventricular function with some residual pulmonary arterial 
 hypertension 
DISSCUSION POINTS 
 
the phenomenon of heparin resistance has unclear clinical significance 
Would fibrinolitic therapy be indicated in this patient? 
Maybe but: time frame and intermediate risk PE 
 
Thank you for attention 
